Traditionally, migraine is thought of as an issue of lost productivity, but there is evidence that there are direct costs on the medical claims side, said Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Group on Health.
Traditionally, migraine is thought of as an issue of lost productivity, but there is evidence that there are direct costs on the medical claims side, said Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Group on Health.
Transcript
How are employers managing their employees who have migraines that might result in presenteeism or absenteeism?
So, historically, employers have not paid very much attention to migraine. They don’t see it a lot in their direct costs. It’s actually there in direct costs. We just completed a study that shows that migraineurs do cost significantly more on the medical claims side than non-migraineurs. But it’s traditionally thought of as a lost-productivity issue—absence from the job or not being able to do the full days’ job, which is call presenteeism.
With a new class of migraine preventive drugs that are not inexpensive, I think there is some renewed employer interest in at least knowing how many migraineurs do we have, what might the cost be to us in the future? So, we are doing a lot of education of employers on how to identify the migraineurs, because migraine is actually highly underdiagnosed. And so, if you look at your claims data, you might say, “I have 2% or 3% migraine rate,” when we know that the truth is for younger females the migraine rate could be 15% to 20%.
So, employers need to look at their data differently. And also need to get, I think, a little bit more invested in: how are we actually going to measure the indirect costs of the lost productivity? Most employers I talk to say, “We know lost productivity is important. W either don’t believe the measures are valid or we don’t know how to implement the measures. Or my [chief financial officer] is not asking for that information.”
So, there’s a tremendous amount that has to change—not just for migraine but for other conditions—to say, “Lost productivity is a truly important cost that needs to be managed.”
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More